Diabetic gastroparesis: Effect of mitemcinal by subgroup analysis in a 12-week, randomized, multi-center, double-blind, placebo-controlled, phase 2b study

被引：0
|
作者：
McCallum, Richard W.
Goldstein, Barry J.
机构：
来源：
GASTROENTEROLOGY | 2006年 / 130卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A598 / A598
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of mitemcinal fumarate (GM-611) in diabetic gastroparesis: 12-week, multi-center, double-blind, placebo-contolled, phase 2b study (GM-611-05)
    Faichney, JD
    Goldstein, BJ
    Fogel, RP
    Mccallum, RW
    DIABETES, 2005, 54 : A512 - A512
  • [2] Mitemcinal fumarate (GM-611) provided symptomatic relief of diabetic gastroparesis, especially in type 1 diabetes: Results of a 12-week, multi-center, double-blind, placebo-controlled, randomized phase 2B study (GM-611-05)
    McCallum, RW
    Fogel, R
    Fang, JC
    Altman, RS
    Faichney, JD
    Goldstein, BJ
    GASTROENTEROLOGY, 2005, 128 (04) : A467 - A467
  • [3] Eliapixant in Refractory Chronic Cough: The 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2b PAGANINI Study
    Dicpinigaitis, P.
    Morice, A. H.
    Smith, J.
    Sher, M. R.
    Vaezi, M.
    Guilleminault, L.
    Niimi, A.
    Krahn, U.
    Saarinen, R.
    Pires, P. Vieira
    Wosnitza, M.
    Mcgarvey, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [4] RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS: EFFICACY AND SAFETY RESULTS FROM A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-WEEK STUDY (RM-131-009)
    Camilleri, Michael
    McCallum, Richard W.
    Tack, Jan F.
    Spence, Sharon C.
    Gottesdiener, Keith
    Fiedorek, Fred T.
    GASTROENTEROLOGY, 2017, 152 (05) : S139 - S140
  • [5] A randomized, double-blind, placebo-controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis
    Abell, Thomas L.
    Kuo, Braden
    Esfandyari, Tuba
    Pfeifer, Nathan D.
    Grimaldi, Maria
    Renzulli, Cecilia
    Tacchi, Raffaella
    Zhou, Kefei
    Barnes, Chris N.
    Nguyen, Deanna D.
    Nguyen, Linda
    Talley, Nicholas J.
    McCallum, Richard
    NEUROGASTROENTEROLOGY AND MOTILITY, 2023, 35 (04):
  • [6] A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-WEEK STUDY OF ENCENICLINE OR PLACEBO IN SCHIZOPHRENIA SUBJECTS ON CHRONIC STABLE ATYPICAL ANTIPSYCHOTIC THERAPY
    Lombardo, I.
    Dgetluck, N.
    Hilt, D.
    Koenig, G.
    Loewen, G.
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S321 - S322
  • [7] A 12-Week, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Phase-2, Dose Selection Study of Lorcaserin Hydrochloride for Smoking Cessation: Preliminary Report
    Wilcox, Charles
    Tong, My-Linh
    Oskooilar, Nader
    Morrissey, Judy
    De Francisco, Don
    Henry, Mellissa
    Badgett, Lynn
    Grosz, Daniel
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S626 - S627
  • [8] Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis
    McCallum, R. W.
    Lembo, A.
    Esfandyari, T.
    Bhandari, B. R.
    Ejskjaer, N.
    Cosentino, C.
    Helton, N.
    Mondou, E.
    Quinn, J.
    Rousseau, F.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2013, 25 (11): : E705 - E717
  • [9] Yogliptin monotherapy in type 2 diabetes: A 12-week randomized, double-blind, placebo-controlled phase II study
    Wang, Xin
    Wang, Ying
    Yong, Xiaolan
    Wu, Bojun
    Sun, Zilin
    Lou, Ning
    Wen, Qing
    Zhang, Yufang
    Li, Shiyun
    Li, Jiarui
    He, Yan
    Cheng, Jinluo
    Zhong, Xiangdong
    Shen, Jing
    Yang, Wenying
    JOURNAL OF DIABETES, 2022, 14 (12) : 822 - 830
  • [10] Risperidone for severe tardive dyskinesia: A 12-week randomized, double-blind, placebo-controlled study
    Bai, YM
    Yu, SC
    Lin, CC
    JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (11) : 1342 - 1348
12345